Safety and efficacy of eculizumab in the prevention of antibody‐mediated rejection in living‐donor kidney transplant recipients requiring desensitization therapy: A randomized trial

We report results of a phase 2, randomized, multicenter, open‐label, two‐arm study evaluating the safety and efficacy of eculizumab in preventing acute antibody‐mediated rejection (AMR) in sensitized recipients of living‐donor kidney transplants requiring pretransplant desensitization (NCT01399593)....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Transplant
Asıl Yazarlar: Marks, William H., Mamode, Nizam, Montgomery, Robert A., Stegall, Mark D., Ratner, Lloyd E., Cornell, Lynn D., Rowshani, Ajda T., Colvin, Robert B., Dain, Bradley, Boice, Judith A., Glotz, Denis
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
ORIGINAL ARTICLES
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790671/
https://ncbi.nlm.nih.gov/pubmed/30887675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.15364
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller